Humana Antidilutive Securities Excluded from EPS increased by 416.2% to 2.3M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.6%, from 1.8M to 2.3M.
A high number of excluded antidilutive securities suggests that a significant portion of employee or convertible incentives are currently 'out of the money' relative to the current stock price.
This metric quantifies the number of potential common shares, such as stock options or convertible securities, that are...
Most public companies disclose this in the notes to the financial statements or the EPS reconciliation table, making it a standard metric for assessing potential future share dilution.
jnj_antidilutive_securities_excluded_from_eps| Q3 '21 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 136K | 98K | 78K | 538K | 78K | 137K | 1.2M | 751K | 361K | 1.8M | 791K | 450K | 2.3M |
| QoQ Change | — | -27.9% | -20.4% | +589.7% | -85.5% | +75.6% | +750.4% | -35.5% | -51.9% | +400.6% | -56.2% | -43.1% | +416.2% |
| YoY Change | — | — | -42.6% | — | -20.4% | +75.6% | +116.5% | +862.8% | +163.5% | +55.1% | +5.3% | +24.7% | +28.6% |